Zanvastro: FDA-approved ASO treatment for Alexander disease

ScienceDaily / University of Wisconsin-Madison USA

Overview

The FDA has approved Zanvastro, the first disease-modifying drug for Alexander disease, a rare neurological disorder affecting fewer than one in a million people. Developed through a collaboration between the University of Wisconsin-Madison and Ionis Pharmaceuticals, the treatment targets the underlying biological cause rather than managing symptoms.

In Depth

Key Findings

Zanvastro is the first approved medication designed to directly treat Alexander disease by targeting the biological process responsible for the condition. Clinical trials indicate that patients receiving the drug generally experienced stabilization of motor function, with some demonstrating improvements in their ability to move.

Technical Details

The drug utilizes antisense oligonucleotides (ASOs), which are short pieces of genetic material designed to interfere with cellular instructions for protein manufacture. Specifically, Zanvastro targets the production of glial fibrillary acidic protein (GFAP). By limiting the production of GFAP, the drug aims to reduce the accumulation of abnormal protein deposits, known as Rosenthal fibers, within astrocytes of the brain and spinal cord.

Due to the requirement to reach the central nervous system, the treatment is administered via injection into the spinal canal once every three months by a healthcare professional.

Background and Context

The development of Zanvastro follows over 30 years of research at the University of Wisconsin-Madison’s School of Veterinary Medicine and Waisman Center. A critical breakthrough occurred in the late 1990s when Albee Messing and Michael Brenner identified the genetic cause of the disease. By genetically engineering mice to produce high levels of GFAP, they unexpectedly created lesions resembling those found in human patients, confirming that mutations in the GFAP gene were the underlying cause.

This discovery shifted the diagnostic process from invasive brain biopsies to genetic testing via blood samples. Subsequent work by Messing and Tracy Hagemann involved creating improved rodent models to test the ASO strategy before human trials began in the summer of 2021.

Significance and Outlook

Alexander disease is a fatal disorder that interferes with movement, cognition, and automatic functions such as heart rate and breathing. Previously, medical options were limited to supportive care for individual symptoms. Zanvastro represents a major advance as the only approved disease-modifying treatment for this rare condition.

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.

• Your email and selected fields are used only to deliver the newsletter.
• We never share your information with third parties.
• You can unsubscribe anytime via the link in each email.

See our Privacy Policy for details.

Agree & Continue ▶

Takes about a minute · Unsubscribe anytime